Roadshow
Stress EEG Assessment (SEA) System
The "Stress EEG Assessment (SEA) System" uses an EEG amplifier, a graphical interface, and a proprietary AI algorithm to analyze 90 seconds brainwave data via the cloud, providing an objective score indicating depression probability.
It enhances physician communication for better awareness and treatment compliance, or serves as a quick mental health screening tool for enterprises and communities.
1.Taiwan FDA-cleared SaMD for diagnosing depression.
2.Clinically validated with 400+ cases; results published in international journals.
3.Safe, non-invasive, radiation-free, and the system is easy to use. Testing process completed in 15 minutes and results available immediately.
Similar to SEA system structure, the BDR system provides objective degeneration probability scores (1-100) that indicates the likelihood of normal aging and mild cognitive impairment (MCI) respectively. This can assist physicians to quickly assess whether a patient is experiencing normal aging, mild cognitive impairment, or has even entered the dementia stage, and order suitable next-steps.
- Established 2019
- Company HippoScreen Neurotech
- Telephone +886-922086486
- Email Tina_chang@hipposceen-nc.com
- Address 2F, No. 578, Ruiguang Rd., Neihu Dist., Taipei City 114728, Taiwan (R.O.C.)
HippoScreen Neurotech focuses on brainwave signal processing and AI technology to develop innovative EEG-based medical solutions. The company is committed to promoting early detection and intervention for mental and neurological health.
Its EEG device has received US FDA 510(k) clearance, Taiwan FDA medical device approval, as well as ISO 13485 and BSI certification.
The Stress EEG Assessment (SEA) System was developed for depression screening and received SaMD approval in Taiwan in 2023, with applications in both clinical settings and non-medical environments such as health checkups and corporate EAPs.
Another product, the Brain Degeneration Risk Assessment System, targets early detection of MCI (Mild Cognitive Impairment) and is currently undergoing clinical trials.
Both products serve as innovative and effective AI-powered tools for not only clinical evaluation but also preventive health screening.